Leukemia Therapeutics Market (2010-2020) (Acute/Chronic lymphocytic leukemia & Acute/Chronic myeloid leukemia) Pipeline forecast & Market forecast in G8 countries

Date: November 22, 2011
Pages: 271
Price:
US$ 5,650.00
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GA7F4C71C61EN
Leaflet:

Download PDF Leaflet

Leukemia Therapeutics Market (2010-2020) (Acute/Chronic lymphocytic leukemia & Acute/Chronic myeloid leukemia) Pipeline forecast & Market forecast in G8 countries
Leukemia is the type of blood cancer and the ninth most common one in males. It accounts for almost 0.0148% of all the men and 0.009% of all the women worldwide. The leukemia market is segmented into four types; namely acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. The market was dominated by chronic myeloid leukemia in 2010. However, in 2020, the market is expected to be equally dominated by acute lymphocytic leukemia and chronic myeloid leukemia.

This report studies the market from 2010 to 2020 covering 29 major regimens and single drugs (off-patent and pipeline) for leukemia treatment. The growing population of leukemia is an impetus for the growth of the market. This market is expected to grow at a CAGR of 3.84% from 2015 to 2020. North America was the major contributor to this market; accounting for 61.95% of the total sales of leukemia drugs in 2010; whereas Gleevec was the major drug accounting for 55.48% of the total sales of leukemia drugs in 2010. Leukemia is still an area with high unmet need for early diagnosis and limited treatment options in this area.

The report studies 19 existing regimens and single drugs for leukemia market. Currently, there are about ten major drugs in pipeline for leukemia; which are expecting a market launch by 2012-2014; Talon Therapeutics Inc submitted new drug application to FDA for Marqibo in July 2011, leading to its market launch by 2012.

Quizartinib will be launched in the market in 2012 by Ambit Biosciences Inc (U.S.) on receiving fast track designation approval from the FDA in 2010. The drug is expected to be priced at $21,129 for patients who take them annually.

Players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to September 2011.

Pipeline drugs form a major growth strategy in the global leukemia therapeutics market accounting for 28% share between January 2008 and September 2011, followed by approvals with a 25% share, and agreements and collaborations with 24% share.

Novartis International AG, GlaxoSmithKline Pharmaceuticals Limited, Roche, Bristol-Myers Squibb, Genmab A/S, Celgene Corporation, and Biogen Idec rule the present market for leukemia drugs; whereas Ambit Bioscience & Pfizer are expected to capture major share of the market by 2020.

Scope of the report

This leukemia therapeutics market research report evaluates the leukemia drugs market with respect to the current and pipeline drugs and regimens. The report analyzes geography; forecasting revenue, and trends in each of the following submarkets:

Chemotherapy regimens
Hyper-CVAD
CALGB 8811 regimen
Linker regimen
FC regimen
FCR regimen
DC regimen
VCD regimen
AVD regimen
Chemotherapy drugs
Gleevec
Sprycel
Tasigna
Clolar
Nelarabine
Oncaspar
Fludara
Campath/MabCampath
Treanda
Arzerra
Cytarabine
Pipeline drugs
Bosutinib
Omapro
Vidaza
Dacogen
Midostaurin
Vosaroxin
Quizartinib
GA101 / RG7159
Graspa
Marqibo

The geographies covered under the report are

North America
U.S.
Canada
Europe
U.K.
Germany
Italy
France
Spain
Japan

Each section provides market data, market drivers, trends and opportunities, key players, and competitive outlook. This report also provides market tables for covering the sub-segments and micro-markets. Additionally, it makes ways for company profiles that cover all the sub-segments. The report has been made by keeping past trends, current happenings and future forecasts in consideration.
1 INTRODUCTION

1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
  1.5.1 MARKET SIZE
  1.5.2 KEY DATA POINTS TAKEN FROM SECONDARY SOURCES
  1.5.3 ASSUMPTIONS MADE FOR THIS REPORT

2 EXECUTIVE SUMMARY

2.1 OVERVIEW OF THE MARKET

3 MARKET OVERVIEW

3.1 DEFINING LEUKEMIA
3.2 DEFINING ACUTE LYMPHOCYTIC LEUKEMIA
  3.2.1 RISK FACTORS
  3.2.2 STAGES/PHASES OF ACUTE LYMPHOCYTIC LEUKEMIA
    3.2.2.1 Childhood ALL
      3.2.2.1.1 Standard (low) risk
      3.2.2.1.2 High risk
      3.2.2.1.3 Recurrent
    3.2.2.2 Adult ALL
      3.2.2.2.1 Untreated adult ALL
      3.2.2.2.2 Adult ALL in remission
      3.2.2.2.3 Recurrent adult ALL
  3.2.3 DIAGNOSIS
    3.2.3.1 Complete Blood Count (CBC)
    3.2.3.2 Biopsy and bone marrow aspiration (CBC)
    3.2.3.3 Spinal tap (lumbar puncture) and cerebrospinal fluid (CSF) analysis
  3.2.4 LEUKEMIA PREVALENCE
  3.2.5 ACUTE LYMPHOCYTIC LEUKEMIA INCIDENCE & MORTALITY
3.3 MARKET STRUCTURE
  3.3.1 KEY THERAPIES
    3.3.1.1 Chemotherapy
    3.3.1.2 Stem cell/bone marrow transplant
    3.3.1.3 Radiation therapy

4 ACUTE LYMPHOCYTIC LEUKEMIA MARKET DYNAMICS

4.1 MARKET OVERVIEW
4.2 BURNING ISSUES
4.3 WINNING IMPERATIVES
  4.3.1 STRATEGY OF MARKET EXPANSION BY UTILIZING MULTIPLE THERAPEUTIC APPROACHES
4.4 MARKET DYNAMICS
  4.4.1 MARKET DRIVERS
    4.4.1.1 Innovative therapies to drive the market for leukemia
    4.4.1.2 Oncology is the largest therapeutic market with high unmet needs
  4.4.2 MARKET RESTRAINTS
    4.4.2.1 Low production capability for efficient drugs
  4.4.3 MARKET OPPORTUNITIES
    4.4.3.1 Limited players in the market
    4.4.3.2 Leukemiaӳ underserved patient populations offer potential for market growth

5 LEUKEMIA PRODUCT MARKET

5.1 MARKET OVERVIEW
  5.1.1 HYPER-CVAD REGIMEN
  5.1.2 CALGB 8811 REGIMEN
  5.1.3 LINKER REGIMEN
  5.1.4 NUCLEOSIDE METABOLIC INHIBITORS (CLOLAR + ARRANON) 52
  5.1.5 ONCASPAR

6 LEUKEMIA DRUG PIPELINE (PHASE III)

6.1 PIPELINE DRUGS
  6.1.1 GRASPA
  6.1.2 MARQIBO

7 GEOGRAPHIC ANALYSIS

7.1 U.S.
7.2 CANADA
7.3 U.K.
7.4 GERMANY
7.5 FRANCE
7.6 ITALY
7.7 SPAIN
7.8 JAPAN

8 COMPETITIVE LANDSCAPE

8.1 INTRODUCTION
8.2 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS/JOINT VENTURES
8.3 NEW PRODUCTS LAUNCH
8.4 EXPANSIONS/NEW FACILITY/INVESTMENTS
8.5 FDA APPROVALS
8.6 CLINICAL TRIALS
8.7 NDA, BLA & MARKETING APPLICATIONS

9 COMPANY PROFILES

9.1 ARIAD PHARMACEUTICALS INC
  9.1.1 OVERVIEW
  9.1.2 FINANCIALS
  9.1.3 PRODUCTS & SERVICES
  9.1.4 DEVELOPMENTS
9.2 ERYTECH PHARMA
  9.2.1 OVERVIEW
  9.2.2 FINANCIALS
  9.2.3 PRODUCTS & SERVICES
  9.2.4 STRATEGY
  9.2.5 DEVELOPMENTS
9.3 GENZYME CORPORATION
  9.3.1 OVERVIEW
  9.3.2 FINANCIALS
  9.3.3 PRODUCTS & SERVICES
  9.3.4 STRATEGY
  9.3.5 DEVELOPMENTS
9.4 TALON THERAPEUTICS INC
  9.4.1 OVERVIEW
  9.4.2 FINANCIALS
  9.4.3 PRODUCTS & SERVICES
  9.4.4 STRATEGY
  9.4.5 DEVELOPMENTS

LIST OF TABLES

TABLE 1 PER COURSE COST OF DRUGS IN NORTH AMERICA & JAPAN, 2011 ($)
TABLE 2 PER COURSE COST OF DRUGS IN EUROPEAN COUNTRIES, 2011 ($)
TABLE 3 DOSAGE PATTERN OF DRUGS
TABLE 4 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY REGIMENS/DRUGS, 2008 - 2020 ($MILLION)
TABLE 5 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS ֠PATENT STATUS
TABLE 6 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY TYPES, 2008 ֠2020 ($MILLION)
TABLE 7 ACUTE LYMPHOCYTIC LEUKEMIA DRUG/REGIMENS MARKET REVENUE, 2008 ֠2020 ($MILLION)
TABLE 8 ACUTE LYMPHOCYTIC LEUKEMIA REGIMEN (HYPER-CVAD) MARKET REVENUE, BY COUNTRY, 2008 ֠2020 ($MILLION)
TABLE 9 ACUTE LYMPHOCYTIC LEUKEMIA REGIMEN (CALGB 8811) MARKET REVENUE, BY COUNTRY, 2008 ֠2020 ($MILLION)
TABLE 10 ACUTE LYMPHOCYITC LEUKEMIA DRUGS (LINKER REGIMEN) MARKET REVENUE, BY COUNTRY, 2008 ֠2020 ($MILLION)
TABLE 11 ACUTE LYMPHOCYTIC LEUKEMIA DRUG CLASS (NUCLEOSIDE METABOLIC INHIBITORS) MARKET REVENUE, BY COUNTRY, 2008 ֠2020 ($MILLION)
TABLE 12 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS (ONCASPAR) MARKET REVENUE, BY COUNTRY, 2008 ֠2020 ($MILLION)
TABLE 13 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS ֠PIPELINE (GRASPA) MARKET REVENUE, BY COUNTRY, 2015 ֠2020 ($MILLION)
TABLE 14 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS ֠PIPELINE (MARQIBO) MARKET REVENUE, BY COUNTRY, 2015 ֠2020 ($MILLION)
TABLE 15 SEER STATISTICS FOR LEUKEMIA (ESTIMATED) IN U.S., 2011
TABLE 16 U.S: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 ֠2020 ($MILLION)
TABLE 17 U.S: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS ֠PIPELINE MARKET REVENUE, BY DRUGS, 2008 ֠2020 ($MILLION)
TABLE 18 CANADA: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 ֠2020 ($MILLION)
TABLE 19 CANADA: LEUKEMIA DRUGS ֠PIPELINE MARKET REVENUE, BY DRUGS, 2015 ֠2020 ($MILLION)
TABLE 20 U.K: INCIDENCE BY GENDER & TYPE OF LEUKEMIA, 2010
TABLE 21 U.K: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 ֠2020 ($MILLION)
TABLE 22 U.K: LEUKEMIA DRUGS ֠PIPELINE MARKET REVENUE, BY DRUGS, 2015 ֠2020 ($MILLION)
TABLE 23 GERMANY: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 ֠2020 ($MILLION)
TABLE 24 GERMANY: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS ֠PIPELINE MARKET REVENUE, BY DRUGS, 2015 ֠2020 ($MILLION)
TABLE 25 FRANCE: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 ֠2020 ($MILLION)
TABLE 26 FRANCE: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS ֠PIPELINE MARKET REVENUE, BY DRUGS, 2015 ֠2020 ($MILLION)
TABLE 27 ITALY: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 ֠2020 ($MILLION)
TABLE 28 ITALY: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS ֠PIPELINE MARKET REVENUE, BY DRUGS, 2015 ֠2020 ($MILLION)
TABLE 29 SPAIN: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 ֠2020 ($MILLION)
TABLE 30 SPAIN: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS ֠PIPELINE MARKET REVENUE, BY DRUGS, 2008 ֠2020 ($MILLION)
TABLE 31 JAPAN: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 ֠2020 ($MILLION)
TABLE 32 JAPAN: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS ֠PIPELINE MARKET REVENUE, BY DRUGS, 2008 ֠2020 ($MILLION)
TABLE 33 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS/JOINT VENTURES
TABLE 34 NEW PRODUCTS LAUNCH, 2008 ֠2011
TABLE 35 EXPANSIONS/NEW FACILITY/INVESTMENTS, 2011
TABLE 36 FDA APPROVALS, 2008 ֠2011
TABLE 37 CLINICAL TRIALS, 2008 ֠2011
TABLE 38 NDA, BLA & MARKETING APPLICATIONS, 2008 ֠2011
TABLE 39 ARIAD PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2008 ֠2010 ($MILLION)
TABLE 40 ARIAD PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 41 ERYTECH PHARMA: PRODUCT PIPELINE
TABLE 42 GENZYME CORP.: TOTAL REVENUE AND R&D EXPENSES, 2008 ֠2010 ($MILLION)
TABLE 43 GENZYME CORP.: PRODUCT PORTFOLIO
TABLE 44 TALON THERAPEUTICS INC: TOTAL R&D EXPENSES, 2008 ֠2010 ($MILLION)
TABLE 45 TALON THERAPEUTICS INC: PIPELINE PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1 TOTAL ACUTE LYMPHOCYTIC LEUKEMIA MARKET, 2008 ֠2020 ($MILLION)
FIGURE 2 ACUTE LEUKEMIA MARKET REVENUE, BY REGIMENS/DRUGS, 2008 ֠2020 ($MILLION)
FIGURE 3 TYPES OF LEUKEMIA
FIGURE 4 TOTAL LEUKEMIA POPULATION, BY COUNTRY, 2008-2020
FIGURE 5 ACUTE LYMPHOCYTIC LEUKEMIA DEVELOPMENT & PROGRESSION RATE, BY AGE
FIGURE 6 STAGES AND PHASES OF ACUTE LYMPHOCYTIC LEUKEMIA
FIGURE 7 ACUTE LYMPHOCYTIC LEUKEMIA POPULATION, BY COUNTRY, 2008 ֠2020
FIGURE 8 ACUTE LYMPHOCYTIC LEUKEMIA: MARKET SEGMENTATION, BY REGIMENS/DRUGS
FIGURE 9 ACUTE LYMPHOCYTIC LEUKEMIA: EXISTING DRUGS MARKET SHARE, 2010 VS 2020
FIGURE 10 ACUTE LYMPHOCYTIC LEUKEMIA: PIPELINE DRUGS MARKET SHARE, 2015 VS 2020
FIGURE 11 ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 12 ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 13 U.S: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020 ($MILLION)
FIGURE 14 U.S: ACUTE LYMPHOCYTIC PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 15 CANADA: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 16 CANADA: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 17 U.K: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 18 U.K: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 19 GERMANY: ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 20 GERMANY: ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 21 FRANCE: ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 22 FRANCE: ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 23 ITALY: ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 24 ITALY: ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 25 SPAIN ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 26 SPAIN: ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 ֠2020
FIGURE 27 JAPAN: ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 28 JAPAN: ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 29 KEY GROWTH STRATEGIES (JANUARY 2008 ֠SEPTEMBER 2011)
Skip to top


Ask Your Question

Leukemia Therapeutics Market (2010-2020) (Acute/Chronic lymphocytic leukemia & Acute/Chronic myeloid leukemia) Pipeline forecast & Market forecast in G8 countries
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: